Inhibikase Therapeutics @inhibikase
Inhibikase (Nasdaq: $IKT) is developing disease-modifying therapeutics for Parkinson's disease to restore functional loss inside & outside of the brain. inhibikase.com Joined February 2021-
Tweets526
-
Followers5K
-
Following61
-
Likes18
Inhibikase CEO, Dr. Milton Werner discusses the potential for IkT-001Pro in cardiopulmonary disease in his Letter to Shareholders. Read the full update here: bit.ly/4d5KcWq $IKT
Risvodetinib represents a potential new approach to altering the course of #ParkinsonsDisease. If you have been diagnosed with #Parkinsons you may be eligible to participate in the 201 clinical trial. Learn more: bit.ly/3qhye8l $IKT
In a new Letter to Shareholders, Inhibikase CEO, Dr. Milton Werner highlights how 2024 is shaping up to be a year of execution across the Company's therapeutic pipeline. Read here: bit.ly/4d5KcWq $IKT
Inhibikase is dedicated to providing new treatment options for people suffering from #Parkinsons. Learn about our development of Risvodetinib, a once-daily oral medication with the potential to halt disease progression & reverse functional loss, here: bit.ly/3r80qLu $IKT
We have enrolled approximately 75% of the patients in the 201 Trial in Parkinson's disease, with the last patient anticipated to enter the trial in June. For additional details from our development program update, visit: bit.ly/4d5KcWq $IKT #Parkinsonsdisease
Inhibikase has provided an update on its ongoing development programs. Read the full Letter to Shareholders here: bit.ly/4d5KcWq $IKT
We are working to advance #Parkinsons treatments through our development of small-molecule kinase inhibitors. Our 201 trial exploring whether risvodetinib can slow or halt PD progression is currently enrolling. Learn more this #ParkinsonsAwarenessMonth: bit.ly/3qhye8l
This year for #ParkinsonsAwarenessMonth, @ParkinsonDotOrg is highlighting an important part of #Parkinsons awareness, educating everyone on the many symptoms that impact daily life and how to address them, through their #ABCsofPD campaign. Learn more here: bit.ly/2wRhqcg
Research is critical to providing treatments to the nearly 1M people in the U.S. with Parkinson's. Inhibikase is enrolling patients in a Phase 2 trial exploring whether Risvodetinib (IkT-148009) can slow or halt disease progression. bit.ly/3qhye8l #WorldParkinsonsDay
Today is #WorldParkinsonsDay! More than 10 million people worldwide are living with Parkinson’s disease, and someone new is diagnosed every 6 minutes in the U.S. alone. Learn about the #ABCsofPD from @ParkinsonDotOrg: bit.ly/2wRhqcg #ParkinsonsAwarenessMonth
Inhibikase is developing novel kinase inhibitor treatments for additional #Parkinsons-related disorders, including multiple system atrophy (MSA), a neurodegenerative disorder that shares the hallmarks of c-Abl activation & alpha-synuclein pathology with PD bit.ly/3fIMwXM
April is #ParkinsonsAwarenessMonth! Inhibikase is dedicated to developing new treatments that have the potential to slow or halt the progression of #Parkinsons disease. Learn about our Phase 2 "201 Trial" which is open and enrolling patients here: bit.ly/3qhye8l $IKT
Inhibikase CEO Dr. Milton Werner comments on the Company's pre-IND meeting with the FDA for IkT-001Pro in pulmonary arterial hypertension. For more info: bit.ly/3VKmokl $IKT
Results from Inhibikase's April 5th meeting with the Office of Cardiology, Hematology, Endocrinology and Nephrology will be reported following receipt of the formal meeting minutes. More info: bit.ly/3VKmokl $IKT
Inhibikase will meet with the Office of Cardiology, Hematology, Endocrinology & Nephrology in the Division of Cardiology & Nephrology at the FDA on April 5 for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. bit.ly/3VKmokl $IKT
Risvodetinib (IkT-148009) is the first oral medication shown to correlate clearance of alpha-synuclein toxicity with functional recovery in a living organism. See more about our development of Risvodetinib for #Parkinsons disease here: bit.ly/3r80qLu $IKT
Today at 8:00am ET, Inhibikase will host a conference call and webcast to discuss its full-year 2023 financial results and business highlights. Watch here: bit.ly/4a7MAtC $IKT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity bit.ly/49d1YUn $IKT
Inhibikase's 201 clinical trial exploring whether Risvodetinib (IkT-148009) can slow or halt progression of #ParkinsonsDisease is currently ongoing and enrolling patients. Learn more about the trial and find out if you are eligible here: bit.ly/3qhye8l #Parkinsons $IKT
Incidence of #ParkinsonsDisease in the U.S. is rising. According to the @ParkinsonDotOrg Parkinson's Prevalence Project, 1.2 million people in the U.S. will be living with #Parkinsons by 2030. More info: bit.ly/42V1i4r
Dean Parry @DeanParryIP
520 Followers 3K Following "Everything we stand for involves questioning the norm. We're all about thinking outside the box."
ACCIDENTAL🌟GENUIS @AOGJ5
27 Followers 142 Following I Am only 24 years of age One who never folds thru all da pain I let my music do all the explaining ILL SHINE ON ANY GIVEN CLOUDY DAY
Charlie Fields @CgfieldsFields
270 Followers 815 Following
Ishfaq Mushtaq @Ishfaq2497878
6 Followers 173 Following
Steven Wiggs @WiggsInsurance
2 Followers 17 Following
Mike Land @MikeLand00099
19 Followers 1K Following
Go Lucky @TreeFanForever
298 Followers 4K Following
Omogbemeh Frank @OmogbemehF60132
222 Followers 996 Following
Julius Martin @AmyPerkins60471
260 Followers 3K Following "https://t.co/HssUVNzrS8: Your Trusted Partner for Verified PayPal Accounts and Secure Transactions"
Amy Simmens @A1ways_Grateful
83 Followers 2K Following
Jason Vietri @jasonvietri
593 Followers 4K Following
DSI, a PLG Company @DSInPharmatics
313 Followers 1K Following DSI is a full service CMC Drug Development Consulting Firm, assisting emerging Biotech and Pharma sponsors with CMC, Regulatory and QA for NCEs & Biologics
Jules Lim @JulesLim3
398 Followers 4K Following
Obioma Obioma @ObiomaOA
117 Followers 916 Following
Tessa Lauri @LauriTessa63933
0 Followers 3 Following
Hargobind Singh Manga.. @MangatHargobind
363 Followers 4K Following CCQ4-Requiem Research Carbon as a Commodity. Carbon Quantum Hydrogen Age=QHZ. Adding, Saving, Creating, Developing and Manufacturing with CCUS, CCS, CCC Tech.
Michael Lawrence @5474Jmks
55 Followers 339 Following
Freddie Goodliffe @FGoodliffe49315
1 Followers 2 Following
Andy Murthi @AndyMurthi
596 Followers 2K Following
Vincent Cheung @VincentChe57757
3 Followers 4 Following
Galactic Walker @galactic_walk
6 Followers 32 Following
Blame Russia, Covid-1.. @ChinJohnKim
23 Followers 166 Following
AKMedicalUnicorn @medical_unicorn
0 Followers 12 Following
TrangTrang Economy @DHTrang94
2K Followers 4K Following News Crypto Daily, Economy, Super Car... #VNXNet
Jordan Dahl @Jorahl
5 Followers 309 Following
Dave @MU72
61 Followers 107 Following
Treaes King @TreaesKing97867
294 Followers 1K Following
Deborah Hall @hal915_hall
32 Followers 336 Following Let's inspire each other to explore, dream, and create unforgettable memories. 🌍✨ #AdventureAwaits #EmbraceTheJourney
soback.eth @charlie______t
796 Followers 2K Following Interested in Ethereum / AI Alignment / Governance Futurism / Digital Art / stuff like @radxchange Presented @ Zuzalu: 'Social Infra. for AI on Ethereum'
Rex Farndon @w885let
13 Followers 99 Following
Keith Tocher @Tocherabercorn
8 Followers 64 Following
chandvirk @chandvirk19
3 Followers 98 Following
GBPharmaUSA @GBPharmaUSA
115 Followers 678 Following Global Bridge Pharmaceutical is a licensed pharmaceutical consulting and distribution company.
hañgags @hagags62426401
0 Followers 14 Following
MathewKaea @KaeaMathew29933
123 Followers 2K Following
David Arnold @DavidAr58830794
103 Followers 198 Following
Stock Picks NYC @StockPicksNYC
23K Followers 24K Following Send me good stocks and I will post the DD. I look for stocks before they fly. Datestamps don't lie. I’m not a financial advisor. Send me the best stock you got
Mark De Zonia (Dezoni.. @MarkDezonia777
164 Followers 3K Following A computer must determine if your wack crazy is my present theory ,because there is no observable intelligence online anymore it dead long ago as far I know.
ミッキー @Q2J8a0H4A4ghVRB
197 Followers 235 Following はじめまして、2,3年前からふらつきがあり、確定診断は出てないけど～多系統萎縮症の疑いと、携帯電話が故障して、こちらでお願いします
Roman Sandutsar @sandutsar
91 Followers 1K Following
HenryJR8 @HenryJR94
22 Followers 45 Following
joooooo333333 @joooooo333333
17 Followers 174 Following
hüseyin çelebi @hsyn_celebi_
39 Followers 126 Following
Matt Hoffman @byMattHoffman
1K Followers 989 Following Assoc. editorial director @Neurology_Live🧠 @IJMSCtweets📔 @CGT_Live🧬 @Contagion_Live🦠 Proud grad of @RowanUniversity🦉
Mar de Miguel @MarJungle
2K Followers 791 Following Biologist & Science Writer @BioWorld @Clarivate. Contributor @elmundoes Music lover, cofounder @JungleIndieRock
BU Parkinson's Diseas.. @BMCParkinsons
317 Followers 211 Following Our Center @The_BMC @BUMedicine is committed to interdisciplinary management of movement disorders, basic + clinical research to advance treatment and #MedEd
Parkinson's Europe �.. @ParkinsonsEU
8K Followers 2K Following 🌷The leading voice for #Parkinson's in Europe since 1992 🌷Supporting the 1.2m Europeans with #Parkinsons and their families 🌷Founder of #WorldParkinsonsDay
ScienceofParkinsons @ScienceofPD
10K Followers 266 Following Personal account of the Director of Research at @CureParkinsonsT - All views my own - Kiwi - Kia kaha - 侘寂
Parkinson's Life @parkinsons_life
6K Followers 694 Following TWITTER ACCOUNT CLOSED - please follow us at our new home: @ParkinsonsEU. The online lifestyle magazine for the international Parkinson's community.
David Moadel @davidmoadel
26K Followers 21K Following Find plenty of options/stock education at: https://t.co/atvRy64DRB (For informational purposes only; I am not licensed to provide investment advice)
Parkinson Society BC @ParkinsonsBC
3K Followers 1K Following Parkinson Society British Columbia empowers people with Parkinson's with resources and services to enable self-management, self-reliance & self-advocacy.
Team Fox @TEAMFOX
16K Followers 900 Following Team Fox is the grassroots fundraising program of @MichaelJFoxOrg. Since 2006, members have raised over $110M to help speed a cure for Parkinson's. 🦊
Parkinson's News Toda.. @parkinsonstory
2K Followers 3 Following We are a free digital publication dedicated to sharing the latest news, research, and Parkinson's disease patient perspectives.
WPC 2023 @WorldPDCongress
7K Followers 934 Following Only global meeting to include ALL members of the Parkinson's community. #WPC2023 #parkinsons #neurology #neuroscience BLOG: https://t.co/3zK88CQ4oS
Mike Tindall @miketindall13
241K Followers 685 Following 🏉 Former rugby player, full-time amateur golfer! ✉️ [email protected] for all enquiries
CamilleBCarroll @CamilleBCarroll
616 Followers 384 Following Parkinson’s neurologist and researcher @PlymUni & @UHP_NHS. Interested in clinical trial design, wearable technology and remote management. Leads PD STAT trial.
anette schrag @a_schrag
387 Followers 65 Following
Richelle Flanagan �.. @RichelleFlan
5K Followers 6K Following Family, Friends, Dietitian, Coeliac/Parkinson’s/ADHD advocate, Life too precious not to smell the🌹Past President INDI; WPC Ambassador. Own Views.
Jill Malandrino @JillMalandrino
20K Followers 3K Following Global Markets Reporter @Nasdaq & Host @TradeTalks #CapitalMarkets #DigitalAssets #Web3 @RutgersU @RutgersCommInfo Grad @UMass Undergrad #PIC @DonaldKey
TradeTalks @TradeTalks
15K Followers 1K Following Where the voices of the market meet. @JillMalandrino hosts conversations with leaders on markets, technology, financial literacy, digital assets, and more.
Therapies for Parkins.. @Therapies4PD
516 Followers 334 Following Information and therapy updates on #Parkinsons disease from Australian PD experts, Neurologist Dr Paul Silberstein and Neurosurgeon Dr Raymond Cook.
Houston Parkinson's @HAPSONLINE
2K Followers 405 Following Houston Area Parkinson Society's mission is to improve the quality of life for those affected by Parkinson's disease through services, education & advocacy.
Parkinson's Disease @ParkinsonRF
4K Followers 43 Following The Parkinson Research Foundation sponsors research, publishes scientific results, and funds education and support programs for those affected by PD.
Parkinson's Humor @YumaBev
4K Followers 2K Following #Parkinsons symptoms since the 80's, finally diagnosed in 2007, bilateral DBS in 2012. Funny stories & helpful tips about life. Come laugh with me 🤣
Jennifer Goldman, MD,.. @JenGoldmanMD
2K Followers 1K Following Parkinson’s & Movement Disorders Neurologist | Consultant | Speaker | Dedicated to finding new ways to improve the lives of people with movement disorders
Nacho Mata @nachogenePD
2K Followers 1K Following neurogeneticist interested in understanding the genetic component of Parkinson’s disease (PD) and related disorders . Fighting for diversity in genetic studies
Jason Crowell @jasonlcrowell
569 Followers 458 Following Neurologist specializing in Parkinson disease and movement disorders
Alex Flynn @AlexFlynn01
2K Followers 2K Following The late Alex Flynn, adventurer diagnosed with Parkinson's Disease at 36yrs. 10MillionMetres&Beyond are continuing to raise funds & awareness in his memory.
Aligning Science Acro.. @ASAP_Research
2K Followers 376 Following Global initiative accelerating #ParkinsonDisease research. Join us on LinkedIn, Threads, or BlueSky.
When Life Gives You P.. @ParkinsonsPod
3K Followers 991 Following A podcast about living with Parkinson's disease featuring Larry Gifford, 48, and Partner in PD Rebecca Email: [email protected]
Journal of Parkinson'.. @journal_PD
5K Followers 245 Following Dedicated to expediting our understanding & improving treatments of PD | Co-Editors-in-Chief: Bas Bloem and Lorraine Kalia
Parkinson's Disease C.. @BIDMC_PD_Center
1K Followers 510 Following David K. Simon, MD, PhD, Professor of Neurology, Harvard Medical School; Research, events & news related to Parkinson’s disease. RTs ≠ endorsement
John Carroll @JohnCendpts
70K Followers 94 Following Working journalist for 46 years, invented FierceBiotech, founded Endpoints News now majority-@FT owned. 201,000 subscribers. These are personal opinions.
FiercePharma @FiercePharma
98K Followers 485 Following Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.
TRAPD @Trapd_atl
28K Followers 228 Following TRAPD PASTRIES (The Real Amazing Pastry Delicacies) Also #Advocate for #PARKINSONSDISEASE... IG @trapd_atl
Team Parkinson's 💙 @TeamParkinsons
2K Followers 274 Following We are #TeamParkinsons💙. A movement of people united to end Parkinson's forever. Join us!
Parkinson's Excellenc.. @ParkinsonsEN
3K Followers 348 Following We are the Parkinson's Excellence Network, bringing health and social care professionals together to transform Parkinson's care. For support @ParkinsonsUK
Parkinson's UK @ParkinsonsUK
75K Followers 6K Following We are Parkinson's UK. Powered by people. Funded by you. Improving life for everyone affected by Parkinson’s. Together we'll find a cure.
Ralph @StuckInStock
6K Followers 443 Following Physician.Masters in Finance. Daily Database analysis of all Macro/Micro/Technical/Fundamental US securities data/SEC files using python. Open for collaboration
Dr. Salomon de Ni Una.. @DrNiUnaDietaMas
110K Followers 2K Following Usen estas 5 ayudas https://t.co/v7lQ01PrQL
RDL_Trader @RobLansinger
1K Followers 2K Following My Tweets, opinions and views are my own and not intended as investment advice. Do your own research... @RDLStockTalk
Genetic Engineering &.. @GENbio
88K Followers 4K Following Serving the biotech industry since 1981. EIC @johnsterling4; publisher @liebertpub Subscribe to GEN: https://t.co/KzqMccOt9Q
FierceBiotech @FierceBiotech
101K Followers 649 Following The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
BioWorld @BioWorld
39K Followers 9K Following Biopharma’s trusted news source. Lynn Yoffee, Jennifer Boggs, Karen Carey, Anette Breindl, Lee Landenberger, Randy Osborne, Mari Serebrov, Caroline Richards
Jonny Acheson @jonny_acheson
7K Followers 1K Following Husband, Dad, EM doc and Artist. Parkinsons since 2016. Director of Engagement @ParkinsonsEN. Thankful for grace. Likes to exercise, loves to draw. Views my own
Robyn Miller @Robyn4FightPD
496 Followers 247 Following I am a Kiwi woman who has been diagnosed with early onset Parkinson's Disease and am fighting it with exercise, diet, prayer, drugs, and positive thinking.
Parkinson's Foundatio.. @PFResearchTeam
990 Followers 136 Following @ParkinsonDotOrg knows that a research breakthrough can happen at any time & believes in educating our PD community with the latest research updates
Jori Fleisher @JoriFleisher
468 Followers 544 Following Movement disorders neurologist, Assoc. Prof. @RushMedical @AANMember @BrainandLifemag #neuropalliative. Mom, cook, 🚴♀️, end #parkinsons. Tweets are mine.
Renzo Figari, MD @FigariRenzo
466 Followers 398 Following UVA Neurology. JHU MEPH Class 2021. Tweets are my own. UPCH 🇵🇪 Alumni. Never tickle a sleeping dragon.
Erik Middlebrooks, MD @EMiddlebrooksMD
8K Followers 2K Following Professor & Associate Chair @MayoClinic, Consultant Neuroradiology & Neurosurgery. President @theSENRS. Treasurer @theASFNR. Senior Editor @theAJNR
Neuroscience News @NeuroscienceNew
450K Followers 6K Following Official Neuroscience News Twitter. Brain research news articles on neuroscience, psychology, AI, neurology, brain cancer, robotics, mental health & science.Inhibikase is recruiting up to 120 untreated Parkinson's patients for its 201 trial of IkT-148009, which just dosed its first participant. buff.ly/3ORQ63N #parkinsons #parkinsonsresearch #parkinsonsdisease #parkinsonsnews
Inhibikase Therapeutics @inhibikase announces the lifting of @US_FDA clinical hold on IkT-148009 in #Parkinsons; The company can now move forward with their 201 clinical trial inhibikase.com/news/press-rel…
Data in preclinical models of #Parkinsons of the brain-penetrant, oral c-Abl inhibitor IkT-148009 from Inhibikase Therapeutics @inhibikase & @JohnsHopkins collaborators; Neuroprotective even when treatment began 4 weeks after initiation of the model science.org/doi/10.1126/sc…
Applying a #DrugDiscovery pipeline, researchers identify a drug candidate for #ParkinsonsDisease that halts neurodegeneration and restores motor function in mice with inherited or sporadic disease. @DawsonValina @HopkinsMedicine @inhibikase scim.ag/1gd
Milton Werner, CEO of @inhibikase, discusses the Phase II 201 trial investigating the use of c-Abl inhibition to treat #Parkinsons Learn more on IkT-148009 as a potential disease-modifying therapy in PD: ow.ly/83VU50Lkcbv #MDSCongress #MovementDisorders #Neurology
The final session of day 1 of #GrandChallengesinPD is focused on c-Abl inhibitors in #Parkinson disease and kicks off with Milton Werner @inhibikase
Now pivoting to c-ABL @VAInstitute Grand Challenges. Dr. Milton Werner from @inhibikase walks us through c-Abl inhibition as a therapeutic for #Parkinsons. Developed neat functional assay to screen for drugs (1/2)
IkT-148009 showed selective inhibition of c-Abl, low organ toxicity, high brain penetration. Great functional response in preclinical models. Clinically? Surprisingly safe in Phase I trial. VERY wide therapeutic range ✅ Green light for efficacy trials! @ParkinsonDotOrg
Great interview with Milton Werner (@inhibikase) about C-Abl targeting as a potential disease-modifying strategy in #Parkinsons Hear more about this approach & novel agent IkT-148009, coming soon to VJNeurology.com! #MDSCongress #MovementDisorders #NeuroTwitter
Data from the phase 1/1b study of IkT-148009 show that IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and #Parkinsons patients. bit.ly/3UcoA0Z $IKT
New clinical trial registered: Inhibikase Therapeutics @inhibikase are initiating a Phase 2 study of their c-ABL inhibitor IkT-148009 in 120 individuals with untreated #Parkinsons; Safety & tolerability of 3 doses; 12-week study clinicaltrials.gov/ct2/show/NCT05…
Inhibikase @inhibikase will be holding a virtual KOL investor event on April 20th, 2022; They will highlight their Phase 1 & Phase 1b data for the company's lead candidate, IkT-148009 (a cABL inhibitor) for #Parkinsons & discuss their Phase 2 plans inhibikase.com/news/press-rel…
Inhibikase Therapeutics @inhibikase announces dosing of first #Parkinsons patient in its Phase 1b clinical trial of IkT-148009 (a selective c-Abl kinase inhibitor) inhibikase.com/news/press-rel…
Columnist Jo Gambosi urges readers to join efforts to promote awareness about Parkinson's disease and raise funds for research. buff.ly/2U9tUYR #parkinsonsdisease #livingwithParkisonsDisease #parkinsonsresearch
Milton Werner, CEO of @inhibikase, provided an update on the Company’s development of IkT-148009 for the treatment of #Parkinsons disease and clinical measures of dosing pharmacokinetics at #Sachs_NIF. Watch here: youtube.com/watch?v=ykvIEK…
.@inhibikase President & CEO Milton Werner joins @JillMalandrino on @Nasdaq #TradeTalks to discuss therapies designed to modify Parkinson’s Disease in the brain and GI tract. x.com/i/broadcasts/1…
Dr. Milton Werner is the President and CEO of Inhibikase Therapeutics, a company developing novel protein kinase inhibitor therapeutics to treat neurodegenerative disease and viral infection inside and outside of the brain. e-Meet Dr. Milton Werner at #Sachs_NIF
Today is #WorldParkinsonsDay! Take the #KnowMorePD quiz today to test your knowledge of Parkinson’s disease: Parkinson.org/KnowMorePD #Together4PD #TogetherApart Retweet so others can show what they know too 🧠 Let's #KnowMorePD until there is NO more PD!
Milton Werner, President & CEO will be presenting Inhibikase Therapeutics, Inc.(@inhibikase) at the upcoming Neuroscience Innovation Forum. e-Meet Inhibikase Therapeutics, Inc. at #Sachs_NIF More info @ sachsforum.com/4nif-about.html
Trends for United States
You might like
